Why is Gilead Sciences stock surging today?
Gilead Sciences (GILD) stock rose 2.9% in after-hours trading to $170.40 after beating Q3 2026 earnings expectations with adjusted EPS of $2.55 and revenue of $8.3 billion. The company raised full-year 2026 product sales guidance to $31.0-$31.3 billion. The HIV franchise, including Biktarvy and Yeztugo, drove growth, with HIV prevention sales nearly doubling year-over-year. Jefferies raised its price target to $185 ahead of the report.
How this was made
The 30-second read
Why it matters
A beat on both EPS and revenue, combined with a meaningful full-year product sales guidance raise, provides a direct fundamental catalyst for repricing, consistent with the after-hours jump.
Market read
Company-specific earnings and guidance details are likely to drive near-term positioning and volatility around follow-through expectations.
What to watch
The article does not discuss margins, pipeline risk, or competitive dynamics; traders may need to verify whether the guidance raise is driven by durable demand versus temporary factors.
Background
The piece frames Gilead’s Q3 2026 results as the strongest year-over-year base business growth in more than a decade, with HIV franchise acceleration as the key driver.
Ticker impact
Gilead reported a Q3 2026 EPS and revenue beat and raised full-year 2026 product sales guidance, driving a 2.9% after-hours surge.
Likely upward pressure as traders price in higher 2026 product sales and stronger HIV franchise growth.
The article cites specific EPS, revenue, and guidance numbers plus a same-day after-hours move tied directly to the results.
Market effects
Reinforces positive read-through for HIV franchise demand and for large-cap pharma earnings quality, potentially supporting sentiment toward healthcare earnings into the next cycle.
Primarily US-focused repricing given the after-hours move and US index weakness mentioned.
Limited direct global spillover beyond broader pharma sentiment, since the catalyst is company-specific earnings and guidance.
Counterpoint
The stock’s move may be front-loaded on the beat, and investors could later focus on whether HIV prevention growth and Yeztugo ramp can sustain at the raised guidance midpoint.
Key entities
- companyGilead Sciences
Subject of the article, reporting Q3 2026 results and raising full-year 2026 product sales guidance.
- productBiktarvy
Flagship HIV treatment cited with $4.1B sales and 10% year-over-year growth.
- productYeztugo
Injectable HIV prevention drug cited as continuing a rapid commercial ramp.
- executiveDaniel O’Day
CEO quoted describing the results as the strongest year-over-year base business growth in more than a decade.
